News | Cardiovascular Ultrasound | May 24, 2017

3-D Echo Image Analysis With Philips' HeartModel A.I. is Accurate and Reproducible

Researchers in multicenter study find automated 3D echocardiographic analysis of left-heart chambers an accurate alternative to manual methodology

3-D Echo Image Analysis With Philips' HeartModel A.I. is Accurate and Reproducible

May 24, 2017 — Philips recently announced the results from a global study indicating that automated three-dimensional echocardiographic (3DE) analysis of left-heart chambers is an accurate alternative to conventional manual methodology. This multicenter study assessed Philips HeartModel A.I. Anatomically Intelligent Ultrasound (AIUS) software and builds on the conclusions of the previous clinical assessments carried out at individual locations by affirming consistency and reproducibility across multiple laboratories.

Published in European Heart Journal, the study aimed to determine the accuracy and reproducibility of three different heart measurements in a multicenter setting: left atrial (LA) volume, left ventricular (LV) volume and ejection fraction (EF). Researchers imaged 180 patients across six sites using 3DE with the Philips Epiq ultrasound system. All images were analyzed using automated Philips HeartModel A.I. software, which brings advanced quantification, automated 3-D views and robust reproducibility to cardiac ultrasound imaging.

"The days of time-consuming, difficult collection and analysis of heart measurements are behind us," said Roberto Lang, M.D., professor of medicine and director of noninvasive cardiac imaging laboratories, University of Chicago Medicine. "The results of this study provide further evidence that 3DE technology like Philips HeartModel A.I. is the way forward for global health systems to save time and gather accurate data for quality care delivery to patients."

Current medical guidelines recommend 3DE chamber quantification for patients undergoing an echocardiography exam, but adoption in clinical practice has lagged due to time-consuming analysis that has traditionally been associated with the process. By showing that experienced readers in different parts of the world can obtain accurate and reproducible automated measurements of LVEDV, LVESV and LVEF with clinically non-significant differences, this research demonstrates that HeartModel A.I.. is a time-saving option that yields consistent, reproducible results across laboratories.

These findings could contribute to fuller integration of 3DE quantification into clinical routine. Automated 3DE provides a comprehensive picture of heart function with real-time results, which can help clinicians assess and diagnose patients quickly and confidently.

Philips HeartModel A.I. is designed to allow clinicians and researchers to quickly, easily and confidently assess disease states and determine treatment. Anatomical Intelligence is used in Philips imaging solutions such as Epiq, Affiniti and EchoNavigator.

For more information: www.usa.philips.com/healthcare

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init